Shots:

• The (PK bridging) study evaluates GTX-104 in a ratio (1:1) in 50 patients with SAH. The results are expected in H1’22
• The trial met its EPs for Cmax on Day 1 & area under the concentration-time curve (AUC 0-24hrs.) on Day 3 & continue under the current infusion protocol to its completion. The overall objective is to evaluate the bioavailability of GTX-104 over oral nimodipine capsules & the secondary objective is to assess the safety & tolerability of GTX-104
• The P-III safety study of GTX-104 is expected to initiate in H2’21 & will finalize the study design & protocol based on final study results. GTX-104 is a novel, aqueous formulation of nimodipine developed as an IV infusion for SAH

 Ref: Globe Newswire | Image: Acasti Pharma